Boryung Pharm’s antihypertensive Kanarb family achieves over KRW 5 billion monthly sales
The Boryung Pharm’s ‘Kanarb(generic name: fimasartan) family,’ Korea’s first novel hypertension treatments, achieved KRW 5 billion monthly prescriptions.
The Boryung Pharm’s Kanarb family, including 4 drugs, such as Kanarb, Kanarb Plus(diuretic, Dong Wha Pharm’s Korean product name: Lacor), Duka...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
